Swiss Group for Clinical Cancer Research
- Country
- 🇨🇭Switzerland
- Ownership
- Private
- Established
- 1965-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.sakk.ch/
Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)
- Conditions
- Sarcoma,Soft Tissue
- Interventions
- Other: HyperthermiaRadiation: RadiotherapyProcedure: Surgery
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 24
- Registration Number
- NCT06835049
- Locations
- 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭Universitaetsspital Basel, Basel, Switzerland
🇨🇭EOC - Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 50
- Registration Number
- NCT06452394
- Locations
- 🇨🇭
Kantonsspital St.Gallen, St. Gallen, SG, Switzerland
🇨🇭Clinique de Genolier, Genolier, VD, Switzerland
🇨🇭Kantonsspital Graubünden, Chur, GR, Switzerland
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Other: Standard of care
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 162
- Registration Number
- NCT06401980
- Locations
- 🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland
🇨🇭Inselspital, Bern, Switzerland
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
- Conditions
- Triple-negative Breast CancerTNBC - Triple-Negative Breast Cancer
- Interventions
- Other: neoadjuvant immuno-chemotherapy
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 54
- Registration Number
- NCT06358573
- Locations
- 🇨🇭
Tumor Zentrum Aarau, Aarau, Switzerland
🇨🇭St. Claraspital, Basel, Switzerland
🇨🇭EOC - IOSI Ospedale regionale Bellinzona e valli - San Giovanni, Bellinzona, Switzerland
Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients
- Conditions
- Non-small Cell Lung Cancer (NSCLC)Stage IV
- Interventions
- Other: Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)Radiation: RadiotherapyOther: Surgery
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 128
- Registration Number
- NCT06114108
- Locations
- 🇨🇭
Kantonspital Aarau, Aarau, Switzerland
🇨🇭IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland
🇨🇭Kantonsspital Graubuenden, Chur, Switzerland
LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma
- Conditions
- Non-hodgkin Lymphoma, B Cell
- Interventions
- Diagnostic Test: ctDNA detection
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 64
- Registration Number
- NCT06090162
- Locations
- 🇨🇭
Universitätsspital Basel, Basel, Switzerland
🇨🇭Kantonspital Aarau, Aarau, Switzerland
🇨🇭Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 11
- Registration Number
- NCT04629781
- Locations
- 🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland
🇨🇭Kantonsspital St. Gallen, St. Gallen, Switzerland
🇨🇭IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
- Conditions
- Bladder Cancer
- Interventions
- Drug: Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 46
- Registration Number
- NCT04630730
- Locations
- 🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭Universitaetsspital Basel, Basel, Switzerland
🇨🇭Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland
Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 260
- Registration Number
- NCT04604067
- Locations
- 🇮🇹
Ospedale Papa Giovanni XXIII, Bergamo, Italy
🇮🇹Azienda Ospedaliera Universitaria Maggiore della Carita di Novara, Novara, Italy
🇮🇹Policlinico Agostino Gemelli, Roma, Italy
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
- Conditions
- Malignant Pleural MesotheliomaNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 68
- Registration Number
- NCT04480372
- Locations
- 🇨🇭
HFR Fribourg, Fribourg, Villars-sur-Glâne, Switzerland
🇨🇭St. Claraspital, Basel, Switzerland
🇨🇭Kantonsspital St. Gallen, St. Gallen, Switzerland